Launch of Weekly Shot of Semaglutide - ERIS Lifesciences Ltd

Code BSE: 540596 NSE:

Eris Lifesciences Limited a leading Indian branded formulations company, today announced a breakthrough step in expanding access to advanced diabetes care with the launch of its generic Semaglutide under the brand ‘SUNDAE’ in India. Reinforcing its commitment as a responsible stakeholder in addressing the country’s growing diabetes burden, Eris is introducing SUNDAE in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population. The Company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of Rs 4,000 Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.